

**AMENDMENTS TO THE CLAIMS**

Applicants have submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikethroughs and/or double bracketing.

Please amend pending claims 2-3 as noted below.

1. (Previously Presented) A method for treating constipation in a human patient receiving opioids chronically, comprising administering orally to the patient receiving opioids chronically a dose of a quaternary derivative of noroxymorphone in an amount to achieve laxation within 24 hours, wherein said amount is such that peak plasma concentrations of the quaternary derivative of noroxymorphone do not exceed 100 ng/ml.
2. (Currently Amended) The method of claim 1, wherein the patient is receiving an oral dose of between 30 and 100 mg/day of methadone ~~[[()]]~~ or a dose of another opioid which is a morphine equivalent dose of between 30 and 100 oral mg/day of methadone~~[[()]]~~.
3. (Currently Amended) The method of claim 1, wherein the patient is receiving an oral dose of between 41 and 100 mg/day of methadone ~~[[()]]~~ or a dose of another opioid which is a morphine equivalent dose of between 41 and 100 oral mg/day of methadone~~[[()]]~~.
4. (Previously Presented) The method of claim 1, wherein the quaternary derivative of noroxymorphone is administered in an amount to achieve laxation within 10 hours.
5. (Previously Presented) The method of claim 1, wherein the dose of the quaternary derivative of noroxymorphone is between 0.3 and 3.0 mg/kg.
6. (Original) The method of claim 1, wherein the quaternary derivative of noroxymorphone is not enteric coated.

7. (Original) The method of claim 1, wherein the quaternary derivative of noroxymorphone is enteric coated.
8. (Previously Presented) The method of any of claims 1-7, wherein the quaternary derivative or noroxymorphone is methylnaltrexone.